BofA warns Fed risks policy mistake with early rate cuts
Charles N. York II, the Chief Operating Officer, Chief Financial Officer, and Secretary of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), a $1.25 billion market cap biotech company, executed a stock transaction recently that involved selling a portion of his shares in the company. According to the SEC filing, York sold 4,370 shares of common stock on February 18 at a weighted average price of $11.963 per share, totaling approximately $52,278. The transaction occurred with the stock trading near its 52-week low of $11.13, though InvestingPro analysis suggests the stock is currently fairly valued.
The sale was conducted to cover York’s tax liabilities arising from the settlement of Restricted Stock Units (RSUs). Prior to the sale, he had acquired shares through the vesting of RSUs on February 15, which added a total of 17,875 shares to his holdings. These transactions were executed at no cost as part of his compensation package. The company maintains strong financial health with a current ratio of 14.62, indicating robust liquidity. InvestingPro data reveals several additional insights about the company’s financial position and future prospects.
Following these transactions, York’s direct ownership in Day One Biopharmaceuticals stands at 252,638 shares. The company, which holds more cash than debt on its balance sheet, is scheduled to report earnings in 4 days, with analysts having recently revised their earnings expectations upward for the upcoming period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.